

Helicobacter pylori

(2002/9/1 2002/5/29)

(10)]

30) (30) (10) (15)

50 [(5) (10) (

Kirby *Helicobacter pylori*

H.pylor .Vandepitte Bauer

%92.9

H.pylori

.%100

Sensitivity test and choosing the best anti
***Helicobacter pylori* therapy**

Saba A.S.H Al-Sultan
Department of Anatomy
College of Medicine
Mosul University

Subhi H.K. Al-Jubouri
Department of Biology
College of Science
Mosul University

ABSTRACT

Susceptibility to the following antibiotics [Ampicillin (10µg), Erythromycin (15µg), Amoxycillin (10µg), Rifadin (30µg), Tetracyclin (30µg), Penicillin (10µg) and

Metronidazole (5µg)] of 50 clinical isolates of *Helicobacter pylori* from despotoc patient was determined by Kirby and Bauer method which modified by Vandepitte. *Helicobacter pylori* isolates showed the highest sensitivity to Amoxycillin. And failure of identification of *Helicobacter pylori* was noted in patient who had been treated with Amoxycllin, Metronidazole, Cimetidine and Antacid in 92.9%. This study also revealed that the patient who had not received proper antibiotics, the gastritis resulting from *Helicobacter pylori* can lead to a more serious conditions like gastric, duodenal and esophageal ulceration's in a rate of 100%.

	<i>Helicobacter pylori</i>		
Duodenitis &	Gastritis & Gastric ulcer		
	(Rollason et al., 1984) <i>H.pylori</i>	duodenal ulceri	
	<i>H.pylori</i>		
	.		
	Peptic ulcer	1992	
.(Lee and Megraud,1996)	Infectious disease	<i>H.pylori</i>	
		<i>H.pylori</i>	
	<i>H.pylori</i>		
Recurrence	()	Eradication	
	:	(Thomas et al., 1994) rate	
		<i>H.pylori</i>	•
			•
			•
			•
		:	
		Bismuth salts	-1
		<i>H.pylori</i>	
		.(Laurence et al., 1992) % (30 -10)	
		H₂-receptor blockers	-2

.....

... Ranitidine Famotidine Cimetidine

%84

H.pylori

.(Humphreys et al., 1988)

Proton pump inhibitors

-3

Omeprazole

H⁺

(H⁺/k⁺ ATPas)

H.pylori

%5

Omeprazole

.(Graham et al., 1996; Han et al., 1996)

Antibiotics

-4

)

H. pylori

Clarithromycin

Erythromycin

Tetracycline

Amoxicillin

(*In-vitro*

Metronidazole

.(Roll et al., 1997; Vakil, 1995) .%20

Amoxicillin

H. pylori

.(David et al., 1996) .

H.pylori

50

-1

(Vandepitte et al., 1991) Vandepitte

Bauer Kirby

H. pylori

)

Gastric antrum

biopsies

(Olympus CLE10

Esophagogastroduodenoscopy

:

³ 1

SEWARD MEDICAL

) Stomaker

(%0.9)

)

100 µl.

5

(

UAC HOUSE

(Skirrow's* + %7 +
 %10 O₂ %5 Gas generating 37 (Jar)
 (Jones et al., 1984) (%98-95) CO₂
H.pylori 7-5
 Pleomorphic
 (Lee and Megraud, 1996) ()
 4-3 ()
³ 2
 100 ³ / (10⁹-10⁸)
 Daivd et al., 1996; Xia et) 5-3
 : (al., 1994

(/)	
10	Ampicillin
15	Erythromycin
10	Amoxicillin
30	Rifadin
30	Tetracycline
10	Penicillin
5	Metronidazole

4

-2

() :

76

*H.pylori**H.pylori**H.pylori*

()

* مغذي النمو Skirrow's: عبارة عن خليط من المضادات الحيوية الآتية:
 Vancomycin (10mg) + Trimethoprim (5mg) + Polymyxin B (25001U) (Skirrow's Supplement)

.....

H.pylori

(1)

(21)
(25) Erythromycin

H.pylori

Amoxicillin
(26) Metronidazol

H.pylori :1

	()			
		%		
12≤	19	90	45	Ampicillin (10μg)
14≤	25	90	45	Erythromycin (15μg)
12≤	21	96	48	Amoxicillin (10μg)
4≤	6	40	20	Rifadin (30μg)
15≤	20	92	46	Tetracycline (30μg)
12≤	16	84	42	Penicillin (10μg)
14≤	26	94	47	Metronidazole (5μg)

50

*

Ampicillin Metronidazol Tetracyclin Erythromycin Penicillin

.(Taylor, 1988) Amoxicillin

%100

Acquired

.(Xia et al., 1993)

Microdilution

H.pylori

.(Xia et al., 1994)

(Lee and Megraud, 1996)

H.pylori

(*In-vitro*)

Deep gastric pits

.(Blecker and Gold, 1997)

(pH=2)

H.pylori

(pH=2)

Graham et al., 1996; Han et)

(al., 1996

H.pylori

(David et al., 1996)

H.pylori

()

(2)

(p<0.001)

%92.9 ()

:

+ Metronidazole 250 mg (2x3) + Amoxicillin 250 mg (2x3) + Cimetidine

+200mg (2x2)

.....

(pH=2)

Amoxycillin

Cimetidine

.Bacteriocidal

Amoxycillin

()

Metronidazole

(Humphreys et al., 1988)

%5 *Clostridium difficile*

.(Glupczynski et al., 1990)

:2

H.pylori

P-		<i>H.pylori</i>		%		
		% -	% +			
	10-8	50	50	5.3	4	Metheprim
	12-4	25	75	5.3	4	Garamycin
	8-4	33.3	66.7	7.9	6	Keflex
	7-5	55.6	44.4	23.7	18	Metronidazol
	16-4	50	50	10.5	8	Amoxicillin
	12-4	60	40	13.1	10	Ampicillin
		66.7	33.3	15.8	12	Amoxicillin + Cimetidine
<0.001		92.9	7.1	18.4	14	Amoxicillin + Metronidazol +Cimetidine + Antacid
				100	76	

*

.(David et al., 1996) David

Metronidazole

%66.7

Amoxycillin

Amoxycillin Ampicillin

H.pylori

Cimetidine

:

.1

.2

.3

.4

H.pylori

(Marshall, 1996)

(3)

%100 *H.pylori*

: 3

H.pylori

	% <i>H.pylori</i>			<i>H.pylori</i>				
				% -	% +	%		
		Zantac	Cimet					
-	40	6.7	53.3	0.0	100	36.5	15	+
- 8	76.5	---	23.5	0.0	100	41.5	17	+ +
-	25	25	50	0.0	100	9.8	4	+
2 -	40	20	40	0.0	100	12.2	5	+
						100	41	

.H.pylori

- Blecker, U. and Gold, B.D., 1997. *Treatment of Helicobacter pylori* infection a review , Ped . Infect. Dis. J, 16(4), pp.391-9.
- Cabot, R.C., 1995. Case records of the Massachusetts general hospital in USA, NenglJ.Med ., 332 (17), pp.1153-1159.
- David, Y, Graham, M.D., Wink, A. B. and Guido , N.J.T., 1996. Choosing the best anti-*Helicobacter pylori* therapy: Effect of antimicrobial resistance, Am J. Gastroenterol., 91(6), pp.1072-1076.
- Glupczynski, Y., Burette, A., Koster, E., Nyst, J.F. and Tenre, M.D.,1990. Metronidazole resistance in *Helicobacter pylori*. Lancet, pp. 976-977
- Graham, D.Y., Genta, R., Evans, D.G., Reedy, R. and Clarridge, J.E., 1996. *Helicobacter pylori* dose not migrate from the antrum to the corpus in response to Omeprazole , Am.J. Gastroenterol ., 91(10), pp.2120-2124.
- Han, S.W., Evans, D.G., El-Zaatari, F.A.K., Go, M.F. and Graham, D.Y., 1996. The interaction of PH, Bile and *Helicobacter pylori* may explain duodenal ulcer, Am.J.GastroenteroL, 91(6),pp.1135-1137.
- Humphreys, H., Bourke, S., Dooley, C., Mckenna, D. and Power, B., 1988. Effect of treatment on *Campylobacter pylori* in peptic disease: arandomised prospective trial. Gut, 29,pp. 279-283.
- Jones, D.M., Lessells , A.M. and Eldridge.J., 1984.*Campylobacterl like - Organisms* on the gastric mucosa: culture, histological and serological studies, J. Clin.PathoL, 37,pp. 1002-1006.
- Laurence, D.R., Bennett, P. N. and Brown, M.J., 1992. Clinical pharmacology ,Churchill livingston , USA, 7th ed, chap. 30,pp. 517-529.
- Lee, A. and Megraud, F., 1996. *Helicobacter pylori* techniques for clinical diagnosis and basic research . WBSAUNDERS COMPANY LTD, Philadelphia. USA., pp. 1-6.
- Marshall, B.J., 1994 . *Helicobacter pylori*. Am.,J. GastroenteroL, 89(8),pp. 116-128.
- Roll , J., Weng , A. and Newman , J., 1997 . Diagnosis and treatment of *Helicobacter pylori* infection among California midcare patients , Arch. Intern. Med., 157,pp.994-998.
- Rollasoh, T.P., Ston, J. and Rhode, J. M., 1984. Spiral organism in endoscopic biopsies of the human stomach , J. Clin. Pathol., 37, pp.23-26.
- Taylor, D.E., 1988 . *Campylobacter pylori*, isolation , characterization and association with chronic gastritis and ulcer, Culture .,9 (1).
- Thomas, J. B., Peter, A. and Noel-Mancuso, D. R., 1994 . *Helicobacter pylori* reinfection rate , in patients with cured duodenal ulcer , Am J.bastroenterol. 89(4), 529-532.
- Vakil, 1995 . *H. pylori* : Two-drug regimen is nearly as cost-effective as cost-effective as quadruple therapy , Modern Medicine , 63(7) ,9.

- Vandepitte, L., Engbaek, K., Piot, P. and Heuck, C.C., 1991 .Basic laboratory procedures in clinical bacteriology , WHO, Geneva.
- Xia, H.X ., Daw, M.A., Beattie, S., Keane, C.T. and Omorain, CA., 1993. Prevalence of metronidazole -resistant *Helicobacter pylori* indyptic patients, IRISH. J. Med . Sci., 162(3), pp.91-94.
- Xia, H.X., Keane, C.T. Beattie, S. and Omorain, CA., 1994 . Standardization of disc diffusion test and its clinical significant for susceptibility testing of Metonidazole against *Helicobacter pylori*, Antimicrob -Agents- Chemother ., 38(10), pp.2357-2361.